Recent findings have started to illustrate the potential benefits of combining SHP2 inhibitors with ICB, but the mechanisms by which targeting SHP2 enhances the effects of ICB, especially in a tumor cell autonomous manner, are yet to be fully elucidated (32, 50, 51). Here, PTPN11 is linked to neoplasm.